Carregant...

The Icelandic founder mutation BRCA2 999del5: analysis of expression

INTRODUCTION: A founder mutation in the BRCA2 gene (BRCA2 999del5) accounts for 7–8% of female breast cancers and for 40% of male breast cancers in Iceland. If expressed, the mutant gene would encode a protein consisting of the first 256 amino acids of the BRCA2 protein. The purpose of this study wa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Mikaelsdottir, Evgenia K, Valgeirsdottir, Sigridur, Eyfjord, Jorunn E, Rafnar, Thorunn
Format: Artigo
Idioma:Inglês
Publicat: BMC 2004
Matèries:
Accés en línia:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC468616/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15217494/
https://ncbi.nlm.nih.govhttps://doi.org/10.1186/bcr785
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!